Table 5Clinical evidence summary: Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP - Severe OSAHS

OutcomesNo of Participants (studies) Follow upQuality of the evidence (GRADE)Relative effect (95 % CI)Anticipated absolute effects
Risk with ControlRisk difference with Mixed (SUP/EDU/BEH) Intervention + CPAP versus Usual Care + CPAP (95% CI)

CPAP Device Usage (hours/night)

Higher is better

4451

(10 studies)

⊕⊝⊝⊝

VERY LOW1,2,3,4

due to risk of bias, inconsistency, imprecision, indirectness

The mean CPAP device usage (hours/night) in the control group was

4.8

The mean CPAP device usage (hours/night) in the intervention groups was

0.82 higher

(0.2 to 1.43 higher)

N deemed adherent (≥ four hours/night)

Higher is better

4015

(9 studies)

⊕⊝⊝⊝

VERY LOW1,3,2,4

due to risk of bias, inconsistency, imprecision indirectness

RR 1.14 (1.04 to 1.26)Moderate
656 per 1000

92 more per 1000

(from 26 more to 171 more)

Withdrawal

4956

(11 studies)

⊕⊝⊝⊝

VERY LOW1,3,2,4

due to risk of bias, inconsistency, imprecision, indirectness

RR 0.64 (0.32 to 1.28)Moderate
136 per 1000

49 fewer per 1000

(from 92 fewer to 38 more)

Quality of Life: Comparison of Change from Baseline Values - QoL: FOSQ-10 - Change from Baseline

Higher is better

176

(1 study)

⊕⊝⊝⊝

VERY LOW1,3,4

due to risk of bias, indirectness, imprecision

The mean quality of life: fosq-10 - in the control groups was

−14.2

The mean quality of life: comparison of change from baseline values - QOL: FOSQ-10 - change from baseline in the intervention groups was

2.9 higher

(0.52 lower to 6.32 higher)

Quality of Life: Comparison of Change from Baseline Values - QoL: SF-36 (PH) - Change from Baseline

Higher is better

2836

(1 study)

⊕⊝⊝⊝

LOW1,4

due to risk of bias, indirectness

The mean quality of life: sf-36 (ph) - in the control groups was 5.9

The mean quality of life: comparison of change from baseline values - QOL: sf-36 (ph) - change from baseline in the intervention groups was

5.7 higher

(4.98 to 6.42 higher)

Quality of Life: Comparison of Values at Endpoint - QoL: FOSQ – Endpoint

Scale from 5-20

Higher is better

177

(1 study)

⊕⊝⊝⊝

LOW1,4

due to risk of bias, indirectness

The mean quality of life: FOSQ - in the control groups was

16.7

The mean quality of life: comparison of values at endpoint - QOL: FOSQ - endpoint in the intervention groups was

0.3 higher

(0.56 lower to 1.16 higher)

Quality of Life: Comparison of Values at Endpoint - QoL: SF-36 (PH) – Endpoint

Scale from 0-100

Higher is better

3014

(3 studies)

⊕⊝⊝⊝

LOW1,4

due to risk of bias, indirectness

The mean quality of life: sf-36 (ph) - in the control groups was 56.9

The mean quality of life: comparison of values at endpoint - QOL: sf-36 (ph) - endpoint in the intervention groups was

4.85 higher

(2.49 to 7.21 higher)

Epworth Sleepiness Scale Score

Scale from 0-24

Lower is better

6388

(8 studies)

⊕⊝⊝⊝

VERY LOW1,3,4

due to risk of bias, imprecision, indirectness

The mean ESS in the control group was 8.4

The mean epworth sleepiness scale score in the intervention groups was

1.32 lower*

(2.48 to 0.16 lower)

Mortality (critical outcome)----Not reported
1

Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

2

Downgraded by 1 or 2 increments for heterogeneity,unexplained by subgroup analysis. Random effect analysis used.

3

Downgraded by one increment if the confidence interval crossed one MID and downgraded by two increments if the confidence interval crossed both MIDs. MID for machine usage (adherence)- 1 hour; Established MIDs for SF-36 physical/mental- 2/3 ; FOSQ- 2 ; ESS −2.5; SAQLI – 2.. GRADE default MID (0.5XSD) used for all other continuous outcomes.

4

Downgraded by 1 or 2 increments because the majority of the evidence included an indirect or very indirect population respectively

*

Not sleepy in both groups.

From: Adherence

Cover of Adherence
Adherence: Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s: Evidence review N.
NICE Guideline, No. 202.
National Guideline Centre (UK).
Copyright © NICE 2021.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.